Uncategorized

Makary’s reported FDA removal could be ‘broad positive’ for biopharma

Published

on

The widely covered impending ouster of FDA Commissioner Marty Makary not long after the exit of controversial biologics head Vinay Prasad highlights the severe turnover rates at the highest rungs of leadership at the health department.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version